Market Overview

Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution


Akorn, Inc. (Nasdaq: AKRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on the Company's New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP, 2.5% and 10%. Akorn intends to re-launch the product shortly.

Akorn's Chief Executive Officer Raj Rai stated, "Phenylephrine represents our first product approval of 2015 and builds on our 14 product approvals in 2014. While IMS Health estimates ophthalmic phenylephrine sales to be approximately $8 million for the three months ending November 30, 2014, we at Akorn believe the market size is significantly larger given that most ophthalmic phenylephrine products are shipped directly to physician and optometrist offices."

"We are excited to bring our non-refrigerated phenylephrine product back to the market shortly and we expect a number of additional FDA approvals and product launches as we continue to progress through 2015," said Rai.

About Phenylephrine Hydrochloride Ophthalmic Solution, USP, 2.5% and 10%

Akorn's Phenylephrine Hydrochloride Ophthalmic Solution, USP, is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil. Phenylephrine is commonly used by optometrists, ophthalmologists and other physicians to dilate patients' pupils before ocular examinations. Akorn's approval represents the second NDA approval for an ophthalmic phenylephrine product following the approval of a competing NDA product in 2013 and the subsequent withdrawal of grandfathered products from the market in 2014.

Following this approval, Akorn's product will compete against the one other approved NDA product. However, Akorn's product does not require refrigeration, providing greater optometrist and physician convenience compared to the competing phenylephrine product.

Akorn's Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% will be available in 2mL and 15mL fill sizes and Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% will be available as a 5mL fill size.

About Akorn, Inc.

Posted-In: News Press Releases


Related Articles (AKRX)

View Comments and Join the Discussion!

Primero Increases Production by 57% in 2014 and Expects a Further 20% Increase in 2015

USD/JPY Advances Higher Tuesday Morning